TRACON Pharmaceuticals (NASDAQ:TCON) Lifted to Buy at StockNews.com

StockNews.com upgraded shares of TRACON Pharmaceuticals (NASDAQ:TCON) from a hold rating to a buy rating in a research report sent to investors on Wednesday.

Separately, HC Wainwright dropped their target price on TRACON Pharmaceuticals from $120.00 to $60.00 and set a buy rating on the stock in a research report on Wednesday, April 3rd.

TRACON Pharmaceuticals Trading Up 29.9 %

Shares of NASDAQ TCON opened at $1.26 on Wednesday. TRACON Pharmaceuticals has a 12-month low of $0.66 and a 12-month high of $14.75. The company has a market cap of $3.38 million, a PE ratio of 1.88 and a beta of 1.25. The stock has a 50 day simple moving average of $1.74 and a 200-day simple moving average of $3.60.

TRACON Pharmaceuticals (NASDAQ:TCON) last posted its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.13). The firm had revenue of $0.10 million for the quarter. During the same period in the previous year, the firm earned ($7.20) earnings per share. Sell-side analysts forecast that TRACON Pharmaceuticals will post -4 earnings per share for the current fiscal year.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.